PDCD1 and pneumonitis: Second, immunotherapy with anti-PD-1/anti-PD-L1 agents may increase the risk of hyper-progressive disease [66, 67], and PD-1 inhibitors might increase the risk of pneumonitis compared to common chemotherapy agents [68].